Unibest
← Back to patent-cliff list

Amezalpat

Tier C — Watch / trade

Amezalpat

Tempest Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets：PPARα

Indications (approved)：Hepatocellular carcinoma, Liver cancer, Cholangiocarcinoma, Non-small cell lung cancer, Colorectal cancer, Urothelial carcinoma, Castration-resistant prostate cancer, Sarcoma

Regional status

US
Phase II
2020-11-01
EU
Phase II
2020-11-01
China
Phase II
2020-11-01
Japan
-

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Amezalpat?

Approved indications include: Hepatocellular carcinoma, Liver cancer, Cholangiocarcinoma, Non-small cell lung cancer, Colorectal cancer, Urothelial carcinoma, Castration-resistant prostate cancer, Sarcoma.

When does the Amezalpat patent expire?

No public expiry year is available for Amezalpat yet; this page updates once verified.

How do I get a quote for Amezalpat intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-30